

Acknowledgements


- Dr. Janet Payeur, USDA, APHIS, VS, NVSL
- Dr. Ray Waters, NADC, ARS
- Dr. Kathy Orloski, USDA, APHIS, VS
- Dr. Chuck Massengill, Missouri Dept. of Agriculture (retired)
- Dr. Mitch Palmer, NADC, ARS
- Dr. Susan Mikota, Elephant Care International
- Dr. Michele Miller, AZA Elephant Veterinary Advisor
- Dr. Kathy Connell, Chair of USAHA TB Committee*

October 2007

- USAHA TB Committee Chair formed the Elephant TB Scientific Advisory Subcommittee
 - Designate a group of experts to provide comment and input on the current (and future) draft guidelines

Members of the (AAZV) working group felt that due to the increasing public awareness and regulatory aspects of elephant tuberculosis that it would be more appropriate to address these under the auspices of the USAHATB committee.

- Background for changes:
 - Elephant TB Stat-Pak® Assay was approved and licensed by USDA, Center for Veterinary Biologics in 2007 as screening test,
 - Publication of peer-reviewed paper using Stat-Pak in elephants showing seroreactivity prior to culture diagnosis and potential use of MAPIA for monitoring response to treatment
 - Data presented to USAHA TB committee



Committee recommended changes to the Guidelines:

- Addition of serological testing using the Chembio®
 ElephantTB STAT-PAK assay to trunk wash cultures for annual testing.
- Mandatory MAPIA follow-up testing for all STAT-PAK reactive samples.
- Reclassification of elephant management groups using both culture and serological results (groups 1-5).
- Increased monitoring/surveillance of seroreactive culturenegative elephants, although these animals would not have any travel restrictions or requirements for treatment (prophylactic treatment is optional).
- Addition of euthanasia option for culture positive elephants.
- Updated necropsy and reference information.

2008 Guidelines

Treatment Recommendations

Group	Treatment options
1 (cult/AB/exp neg)	No tx recommended
2 (cult/AB neg/exp+)	No tx recommended
3 (cult neg/AB+)	No tx recommended If +exposure, may consider prophylactic treatment w/ 2 drugs (2 schedules given)
4 (cult+)	Options: A-treatment w/ 3 drugs over 12-15 months (2 schedules given); allowed to travel after tx B-quarantine w/o treatment; no travel or public contact C- euthanasia
5 (untested)	No tx-no travel or public contact

Background Information

2009/2010

- 16 culture positive elephants alive
 - 6 had no available serological test results
 - 2 treated elephants STAT-Pak non-reactive
 - 8 elephants \$TAT-Pak/MAPIA reactive
- 4 elephants died
 - 4/4 annual trunk wash cultures negative
 - 4/4 STAT-Pak/MAPIA reactive
 - 3/4 *M.tb* complex positive at necropsy
 - One culture negative elephant treated 9 months

Background Information

- Results for elephants tested under 2008
 Guidelines
 - 398 tested out of 451 elephants (8 died during this period)
 - 303 nonreactive on STAT-Pak
 - 95 considered reactive by inspectors
 - 37 showed bands on MAPIA consistent with antibodies to *M. tb* complex
 - 4 died with evidence of TB at necropsy (2 TW+ culture)

Rationale for revisions

- Request for clarification on:
 - classification of treated animals
 - exposed elephants
- Published information on new test DPP
- Additional information
 - Publication of high sensitivity of serological tests antemortem (Greenwald et al, 2009)
 - Report of potential human risk (outbreak among staff at elephant sanctuary)

Rationale for revisions

- Chain of custody for testing animal-side to prevent potential misuse of tests for other regulatory program animals
 - Condition of licensing of test by CVB only NVSL/USDA approved trainees are approved labs
- Exposure history added back as a risk factor for management groups
- Clarified that previously treated elephants may be seroreactive but not be subject to restrictions (upon approval of USDA inspector)

Rationale for revisions

- No management group is REQUIRED to be treated including culture positive elephants
 - Options for culture positivé elephants include:
 - Treatment
 - Euthanasia
 - Quarantine
- NOTE: this was also option in 2008 Guidelines

Rationale for revisions

 Treatment of seroreactive or culture positive elephant is attending veterinarian's choice

 Epidemiological risks as currently known provide basis for current management subgroups and recommendations for monitoring and/treatment

Future Revisions

 USAHA TB Scientific Advisory Subcommittee will continue to review and revise guidelines as new information is presented at the annual meeting in October through the process outlined by USAHA and the TB Committee.

